NCT02692313

Dose Response of Epinephrine

Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial function and atherothrombotic balance in humans. The specific aim of our study will be to determine the dose response effects of the key ANS counterregulatory hormone epinephrine on endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in healthy humans.

Conditions

• Diabetes Complications

Interventions

Type	Name	Description
DRUG	Epinephrine	Dose response of epinephrine infusion
OTHER	Saline infusion	Placebo

Timeline

• Start date: 2016-06-01
• Primary completion: 2025-09-01
• Completion: 2025-09-01
• First posted: 2016-02-26
• Last updated: 2025-10-06

Locations

1 site across 1 country: United States